A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to
Christof T Kaltenmeier1, Laura L Vollmer1, Lawrence A Vernetti1
1Departments of Surgery, Immunology and Biochemistry (C.T.K., M.T.L.), Drug Discovery Institute (L.L.V., L.A.V., L.C., K.D., M.T.L., A.V.), Department of Computational and Systems Biology (L.A.V., A.V.), Department of Pharmaceutical Sciences (V.N.K., B.W.D.), and Department of Developmental Biology (M.T.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Platypus Technologies, LLC, Madison, Wisconsin (K.I.H.).
Abstract:
Dual specificity mitogen-activated protein kinase (MAPK) phosphatases [dual specificity phosphatase/MAP kinase phosphatase (DUSP-MKP)] have been hypothesized to maintain cancer cell survival by buffering excessive MAPK signaling caused by upstream activating oncogenic products. A large and diverse body of literature suggests that genetic depletion of DUSP-MKPs can reduce tumorigenicity, suggesting that hyperactivating MAPK signaling by DUSP-MKP inhibitors could be a novel strategy to selectively affect the transformed phenotype. Through in vivo structure-activity relationship studies in transgenic zebrafish we recently identified a hyperactivator of fibroblast growth factor signaling [(E)-2-benzylidene-5-bromo-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI-215)] that is devoid of developmental toxicity and restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells. Here, we hypothesized that BCI-215 could selectively affect survival of transformed cells. In MDA-MB-231 human breast cancer cells, BCI-215 inhibited cell motility, caused apoptosis but not primary necrosis, and sensitized cells to lymphokine-activated killer cell activity. Mechanistically, BCI-215 induced rapid and sustained phosphorylation of extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) in the absence of reactive oxygen species, and its toxicity was partially rescued by inhibition of p38 but not JNK or ERK. BCI-215 also hyperactivated MKK4/SEK1, suggesting activation of stress responses. Kinase phosphorylation profiling documented BCI-215 selectively activated MAPKs and their downstream substrates, but not receptor tyrosine kinases, SRC family kinases, AKT, mTOR, or DNA damage pathways. Our findings support the hypothesis that BCI-215 causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling, and the findings also identify an intersection with immune cell killing that is worthy of further exploration.
Insights
BCI-215, a novel compound, selectively kills cancer cells by activating mitogen-activated protein kinase (MAPK) signaling pathways, offering a potential new cancer therapy strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Dual specificity mitogen-activated protein kinase (MAPK) phosphatases (DUSP-MKPs) are implicated in cancer cell survival by regulating MAPK signaling.
- Inhibiting DUSP-MKPs to hyperactivate MAPK signaling presents a potential strategy for cancer treatment.
Purpose of the Study:
- To investigate the efficacy of BCI-215, a fibroblast growth factor signaling hyperactivator, in selectively targeting cancer cells.
- To elucidate the molecular mechanisms underlying BCI-215's anti-cancer effects.
Main Methods:
- In vivo structure-activity relationship studies in zebrafish.
- In vitro experiments using MDA-MB-231 human breast cancer cells.
- Kinase phosphorylation profiling and mechanistic studies.
Main Results:
- BCI-215 demonstrated selective cytotoxicity in cancer cells, inhibiting motility and inducing apoptosis.
- The compound activated extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) signaling pathways.
- BCI-215 sensitized cancer cells to immune cell killing and activated stress response pathways.
Conclusions:
- BCI-215 selectively induces cancer cell death via non-redox-mediated MAPK pathway activation.
- BCI-215's interaction with immune cell killing warrants further investigation for therapeutic development.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
